BioCentury | Feb 13, 2021
Deals

Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare

...Inc. (HKEX:1672), Kleiner Perkins, New Enterprise Associates and Rock Springs Capital along with new backers Altium Capital...
BioCentury | Sep 18, 2006
Company News

Duravest management update

...Chicago, Ill. Business: Cardiovascular Hired: Hendrik Hammje as interim CEO, formerly an investment banker at Altium Capital...
BioCentury | Jul 20, 2004
Financial News

Protherics raises L10M

...which is a 7% discount to Monday's close of 51.3p. The deal was underwritten by Altium Capital...
BioCentury | Nov 11, 2003
Financial News

New bank in London

...The new bank initially will operate under the regulatory umbrella of investment bank and broker Altium Capital...
BioCentury | Jul 21, 2003
Analyst Picks & Changes

Analyst picks & changes

...Acambis plc (LSE:ACM; ACAM), Cambridge, U.K. Business: Infectious diseases Altium Capital analyst Samir Devani began coverage with...
BioCentury | Jun 17, 2002
Finance

Ebb & Flow

...up the firm's biotech research in New York. Life science analyst Sam Fazeli resigned from Altium Capital...
BioCentury | May 28, 2002
Finance

Ebb & Flow

...Genzyme (GENZ). "The appointment of a CEO removes the possibility that OGS might get acquired," Altium Capital...
BioCentury | Mar 25, 2002
Finance

What next for Biocompatibles?

...exclusive rights for the U.S. market to Abbott," said Sam Fazeli, life science analyst with Altium Capital...
BioCentury | Jan 7, 2002
Finance

Ebb & Flow

...PFE), Tripos (TRPS) and 3-Dimensional Pharmaceuticals (DDDP) among its customers. Cyprotex will be advised by Altium Capital...
BioCentury | Jan 2, 2002
Financial News

Cyprotex files for IPO

...Cyprotex (Manchester, U.K.) filed for an IPO on London's Alternative Investment Market (AIM). Altium Capital is the...
Items per page:
1 - 10 of 34
BioCentury | Feb 13, 2021
Deals

Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare

...Inc. (HKEX:1672), Kleiner Perkins, New Enterprise Associates and Rock Springs Capital along with new backers Altium Capital...
BioCentury | Sep 18, 2006
Company News

Duravest management update

...Chicago, Ill. Business: Cardiovascular Hired: Hendrik Hammje as interim CEO, formerly an investment banker at Altium Capital...
BioCentury | Jul 20, 2004
Financial News

Protherics raises L10M

...which is a 7% discount to Monday's close of 51.3p. The deal was underwritten by Altium Capital...
BioCentury | Nov 11, 2003
Financial News

New bank in London

...The new bank initially will operate under the regulatory umbrella of investment bank and broker Altium Capital...
BioCentury | Jul 21, 2003
Analyst Picks & Changes

Analyst picks & changes

...Acambis plc (LSE:ACM; ACAM), Cambridge, U.K. Business: Infectious diseases Altium Capital analyst Samir Devani began coverage with...
BioCentury | Jun 17, 2002
Finance

Ebb & Flow

...up the firm's biotech research in New York. Life science analyst Sam Fazeli resigned from Altium Capital...
BioCentury | May 28, 2002
Finance

Ebb & Flow

...Genzyme (GENZ). "The appointment of a CEO removes the possibility that OGS might get acquired," Altium Capital...
BioCentury | Mar 25, 2002
Finance

What next for Biocompatibles?

...exclusive rights for the U.S. market to Abbott," said Sam Fazeli, life science analyst with Altium Capital...
BioCentury | Jan 7, 2002
Finance

Ebb & Flow

...PFE), Tripos (TRPS) and 3-Dimensional Pharmaceuticals (DDDP) among its customers. Cyprotex will be advised by Altium Capital...
BioCentury | Jan 2, 2002
Financial News

Cyprotex files for IPO

...Cyprotex (Manchester, U.K.) filed for an IPO on London's Alternative Investment Market (AIM). Altium Capital is the...
Items per page:
1 - 10 of 34